Condition: Cervical Intraepithelial Neoplasia Grade 2/3 · Human Papilloma Virus Infection Type 16 · Sponsor: PapiVax Biotech, Inc.
The purpose of this Phase 2 study is to compare the effects of administering the PVX4 combination device biologic product (pBI-4 DNA vaccine via electroporation-mediated intramuscular delivery with the TriGrid™ Delivery System) in patients with biopsy-confirmed, human papilloma virus (HPV) 16-associated high grade cervical intraepithelial neoplasia (CIN2/3) as compared to the administration of placebo.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Montefiore Medical Center | The Bronx, New York, United States | Not Yet Recruiting |
| Kaohsiung Chang Gung Memorial Hospital | Kaohsiung, Taiwan, Taiwan | Not Yet Recruiting |
| China Medical University Hospital | Taichung, Taiwan, Taiwan | Not Yet Recruiting |
| Taichung Veterans General Hospital | Taichung, Taiwan, Taiwan | Not Yet Recruiting |
| National Cheng Kung University Hospital | Tainan, Taiwan, Taiwan | Not Yet Recruiting |
| National Taiwan University Hospital | Taipei, Taiwan, Taiwan | Not Yet Recruiting |
| MacKay Memorial Hospital | Taipei, Taiwan, Taiwan | Not Yet Recruiting |
| Taipei Medical University Hospital | Taipei, Taiwan, Taiwan | Not Yet Recruiting |
| Taipei Veterans General Hospital | Taipei, Taiwan, Taiwan | Not Yet Recruiting |
| Linkou Chang Gung Memorial Hospital | Taoyuan, Taiwan, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07454915